Duration of OS was reported for 22.5% (7 of 31) of approvals, of which appropriate control arms for metastatic neutropenic tyrosine receptor kinase solid tumors and advanced pheochromocytoma and/or paraganglioma could not be reliably estimated. This evidence concerns the gene NTRK1 and paraganglioma.